Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index; 1 of the 6 sources its claims cite were checked for support.
Abstract
BACKGROUND: Daratumumab, a monoclonal antibody targeting CD38, has been approved for use with standard myeloma regimens. An evaluation of subcutaneous daratumumab combined with bortezomib, lenalidomide, and dexamethasone (VRd) for the treatment of transplantation-eligible patients with newly diagnosed multiple myeloma is needed. METHODS: In this phase 3 trial, we randomly assigned 709 transplantation-eligible patients with newly diagnosed multiple myeloma to receive either subcutaneous daratumumab combined with VRd induction and consolidation therapy and with lenalidomide maintenance therapy (D-VRd group) or VRd induction and consolidation therapy and lenalidomide maintenance therapy alone (VRd group). The primary end point was progression-free survival. Key secondary end points were a complete response or better and minimal residual disease (MRD)-negative status. RESULTS: At a median follow-up of 47.5 months, the risk of disease progression or death in the D-VRd group was lower than the risk in the VRd group. The estimated percentage of patients with progression-free survival at 48 months was 84.3% in the D-VRd group and 67.7% in the VRd group (hazard ratio for disease progression or death, 0.42; 95% confidence interval, 0.30 to 0.59; P<0.001); the P value crossed the prespecified stopping boundary (P = 0.0126). The percentage of patients with a complete response or better was higher in the D-VRd group than in the VRd group (87.9% vs. 70.1%, P<0.001), as was the percentage of patients with MRD-negative status (75.2% vs. 47.5%, P<0.001). Death occurred in 34 patients in the D-VRd group and 44 patients in the VRd group. Grade 3 or 4 adverse events occurred in most patients in both groups; the most common were neutropenia (62.1% with D-VRd and 51.0% with VRd) and thrombocytopenia (29.1% and 17.3%, respectively). Serious adverse events occurred in 57.0% of the patients in the D-VRd group and 49.3% of those in the VRd group. CONCLUSIONS: The addition of subcutaneous daratumumab to VRd induction and consolidation therapy and to lenalidomide maintenance therapy conferred a significant benefit with respect to progression-free survival among transplantation-eligible patients with newly diagnosed multiple myeloma. (Funded by the European Myeloma Network in collaboration with Janssen Research and Development; PERSEUS ClinicalTrials.gov number, NCT03710603; EudraCT number, 2018-002992-16.).
Overview
CoChat Summary
## TL;DR
The supplementary appendix for the PERSEUS trial describes a randomized comparison of subcutaneous daratumumab plus bortezomib/lenalidomide/dexamethasone (D-VRd) versus VRd alone in transplant-eligible patients with newly diagnosed multiple myeloma. It mainly provides endpoint definitions, statistical methods, eligibility criteria, subgroup results, and safety tables, but not the full primary efficacy narrative.
## Key findings
- The trial’s primary endpoint was progression-free survival; key secondary endpoints were overall complete response or better, overall minimal residual disease (MRD)-negativity, and overall survival.
- At the interim analysis, the primary endpoint was tested at an exact two-sided significance level of 0.0126, determined by 153 progression-free survival events under an Hwang-Shih-DeCani alpha-spending function.
- In prespecified subgroup analyses, D-VRd showed higher overall complete response or better rates and MRD-negativity rates across most reported subgroups; for example, MRD-negativity was 71.1% vs 45.9% in men, 81.3% vs 49.7% in women, and 78.2% vs 46.8% in patients younger than 65 years.
- Safety tables report serious adverse events in 57.0% of D-VRd patients (200/351) versus 49.3% of VRd patients (171/347); infections were the most common serious adverse event category (35.0% vs 27.4%).
## Methods
- Randomized PERSEUS study in transplant-eligible patients with newly diagnosed multiple myeloma; eligible patients were 18 to 70 years old and had ECOG performance status 0 to 2 and specified laboratory/organ-function criteria.
- The appendix specifies an intention-to-treat framework for efficacy endpoints and a safety population of patients who received at least one dose of study treatment; sample sizes in the safety tables were 351 for D-VRd and 347 for VRd.
- Main analyses included progression-free survival with two interim analyses and a final analysis, plus hierarchical testing of key secondary endpoints to control family-wise type I error; subgroup analyses are shown for complete response or better and MRD-negativity.
## Limitations
- The appendix text itself does not report the main trial’s headline efficacy results (for example, hazard ratios or median progression-free survival), so those outcomes cannot be summarized from this text alone.
- The subgroup forest plots note that the widths of confidence intervals were not adjusted for multiplicity and cannot be used to infer treatment effects.
- Evident from the provided text: this is a supplementary appendix only, so it is incomplete as a standalone paper summary.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
1 Valid · 1 Not valid · 3 Not checked · 42 Own results and interpretations
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“| Standard risk | 182/266 (68.4) | 234/264 (88.6) | | 3.60 (2.27–5.70) |”
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“| Non-IgG | 73/96 (76.0) | 72/78 (92.3) | | 3.78 (1.45–9.83) |”
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“| ≥65 years | 62/87 (71.3) | 77/94 (81.9) | | 1.83 (0.91–3.68) |”
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Male | 94/205 (45.9) | 150/211 (71.1) | | 2.90 (1.94–4.35) |”
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“| <65 years | 186/267 (69.7) | 235/261 (90.0) | | 3.94 (2.43–6.37) |”
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
24 more claims
Create a free account to see all 47 claims and every source verdict.
- Probably not a substantial claim. 10
- It may state two separate claims as one. 11
- The quote only partly states this claim. 3
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The quadruplet regimen of daratumumab, bortezomib, lenalidomide, and dexamethasone (Dara-VRd) has recently emerged as standard of care option for initial therapy in transplant eligible patients with newly diagnosed myeloma.101,111”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [101]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The role of daratumumab in patients who received it as part of frontline therapy is unclear.101,152”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [101]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Daratumumab, an anti-CD38–targeting monoclonal antibody (mAb), is a cornerstone of standard-of-care MM regimens with demonstrated survival benefit across all lines.9–14”
From Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma (2026) · cites this paper as [9]
Experimental — accuracy not yet measured
Citations
Cites
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
Rajkumar, S. V., Dimopoulos, M. A., Palumbo, A., Blade, J., Merlini, G., Mateos, M.-V., Kumar, S., Hillengass, J., Kastritis, E., Richardson, P., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70442-5 · Cited by 4,978
Self-citationKumar, S., Paiva, B., Anderson, K. C., Durie, B., Landgren, O., Moreau, P., Munshi, N., Lonial, S., Bladé, J., Mateos, M.-V., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30206-6 · Cited by 3,061
Self-citationLenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma
Attal, M., Lauwers-Cances, V., Hulin, C., Leleu, X., Caillot, D., Escoffre, M., Arnulf, B., Macro, M., Belhadj, K., Garderet, L., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611750 · Cited by 1,257
Self-citationde Weers, M., Tai, Y.-T., van der Veer, M. S., Bakker, J. M., Vink, T., Jacobs, D. C. H., Oomen, L. A., Peipp, M., Valerius, T., Slootstra, J. W., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003032 · Cited by 1,037
Rajkumar, S. V., Harousseau, J.-L., Durie, B., Anderson, K. C., Dimopoulos, M., Kyle, R., Blade, J., Richardson, P., Orlowski, R., Siegel, D., et al. (2011) · Blood · doi:10.1182/blood-2010-10-299487 · Cited by 1,036
Self-citationMoreau, P., Attal, M., Hulin, C., Arnulf, B., Belhadj, K., Benboubker, L., Béné, M. C., Broijl, A., Caillon, H., Caillot, D., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31240-1 · Cited by 967
Self-citationKrejcik, J., Casneuf, T., Nijhof, I. S., Verbist, B., Bald, J., Plesner, T., Syed, K., Liu, K., van de Donk, N. W. C. J., Weiss, B. M., et al. (2016) · Blood · doi:10.1182/blood-2015-12-687749 · Cited by 954
Self-citationMultiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†
Dimopoulos, M. A., Moreau, P., Terpos, E., Mateos, M. V., Zweegman, S., Cook, G., Delforge, M., Hájek, R., Schjesvold, F., Cavo, M., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2020.11.014 · Cited by 900
Self-citationGlobal Burden of Multiple Myeloma: A Systematic Analysis for the Global Burden of Disease Study 2016
Cowan, A. J., Allen, C., Barac, A., Basaleem, H., Bensenor, I., Curado, M. P., Foreman, K., Gupta, R., Harvey, J., Hosgood, H. D., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.2128 · Cited by 631
Overdijk, M. B., Verploegen, S., Bögels, M., van Egmond, M., van Bueren, J. J. L., Mutis, T., Groen, R. W., Breij, E., Martens, A. C., Bleeker, W. K., et al. (2015) · mAbs · doi:10.1080/19420862.2015.1007813 · Cited by 521
Research works printed but not linked: 1
- 7. Kazandjian D. Multiple myeloma epidemiology and survival: a unique malignancy. Semin Oncol 2016;43:676-81.
Cited by
Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management
Rajkumar, S. V. (2024) · American Journal of Hematology · doi:10.1002/ajh.27422 · Cited by 534
Malard, F., Neri, P., Bahlis, N. J., Terpos, E., Moukalled, N., Hungria, V. T. M., Manier, S., & Mohty, M. (2024) · Nature Reviews Disease Primers · doi:10.1038/s41572-024-00529-7 · Cited by 337
Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
Facon, T., Dimopoulos, M.-A., Leleu, X. P., Beksac, M., Pour, L., Hájek, R., Liu, Z., Minarik, J., Moreau, P., Romejko-Jarosinska, J., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2400712 · Cited by 284
Self-citationBelantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma
Hungria, V., Robak, P., Hus, M., Zherebtsova, V., Ward, C., Ho, P. J., Ribas de Almeida, A. C., Hajek, R., Kim, K., Grosicki, S., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2405090 · Cited by 199
Self-citationA Randomized Phase 2 Trial of Felzartamab in Antibody-Mediated Rejection
Mayer, K. A., Schrezenmeier, E., Diebold, M., Halloran, P. F., Schatzl, M., Schranz, S., Haindl, S., Kasbohm, S., Kainz, A., Eskandary, F., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2400763 · Cited by 182
Dimopoulos, M. A., Terpos, E., Boccadoro, M., Moreau, P., Mateos, M.-V., Zweegman, S., Cook, G., Engelhardt, M., Delforge, M., Hajek, R., et al. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01041-x · Cited by 165
“At a median follow-up of 47.5 months, the estimated 4-year PFS was 84.3% versus 67.7% in the DaraVRd and VRd groups (HR 0.42, 95% CI 0.30–0.59; P < 0.001), respectively 55 .”
InfluentialSelf-citationUsmani, S. Z., Facon, T. T. F., Hungria, V., Bahlis, N. J., Venner, C. P., Braunstein, M. J., Pour, L., Martí, J. M., Basu, S., Cohen, Y. C., et al. (2025) · Nature Medicine · doi:10.1038/s41591-024-03485-7 · Cited by 207
“The phase 3 PERSEUS study showed significant and clinically meaningful benefit in terms of PFS (hazard ratio, 0.42; P < 0.001), ≥CR rate (87.9% versus 70.1%; P < 0.001) and MRD-negativity rate (75.2% versus 47.5%; P < 0.001) with D-VRd induction/consolidation followed by daratumumab–lenalidomide maintenance versus VRd…”
InfluentialSelf-citationMoreau, P., Hulin, C., Perrot, A., Arnulf, B., Belhadj, K., Benboubker, L., Zweegman, S., Caillon, H., Caillot, D., Avet‐Loiseau, H., et al. (2024) · The Lancet Oncology · doi:10.1016/s1470-2045(24)00282-1 · Cited by 164
Self-citationDaratumumab or active monitoring for high-risk smoldering multiple myeloma
Dimopoulos, M. A., Voorhees, P. M., Schjesvold, F., Cohen, Y. C., Hungria, V., Sandhu, I., Lindsay, J., Baker, R. I., Suzuki, K., Kosugi, H., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2409029 · Cited by 121
Self-citationLeleu, X. P., Hulin, C., Lambert, J., Bobin, A., Perrot, A., Karlin, L., Roussel, M., Montes, L., Chérel, B., Chalopin, T., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03050-2 · Cited by 153
“The PERSEUS trial (phase 3 DVRd versus VRd) 23 , in the context of patients with multiple myeloma that are TE, reported higher MRD negativity rates at the 10 −6 threshold in DVRd compared with VRd (65.1% versus 32.2%, P 0.0001).”
InfluentialSelf-citationTeclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma
Costa, L. J., Bahlis, N. J., Perrot, A., Nooka, A. K., Lu, J., Pawlyn, C., Mina, R., Caeiro, G., Kentos, A., Hungria, V., et al. (2026) · New England Journal of Medicine · doi:10.1056/nejmoa2514663 · Cited by 119
Self-citationMultiple myeloma: signaling pathways and targeted therapy
Lu, Q., Yang, D., Li, H., Niu, T., & Tong, A. (2024) · Molecular biomedicine · doi:10.1186/s43556-024-00188-w · Cited by 90
Mai, E. K., Bertsch, U., Požek, E., Fenk, R. R., Besemer, B., Hanoun, C., Schroers, R., von Metzler, I., Hänel, M., Mann, C., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco-24-02266 · Cited by 92
Measurable Residual Disease–Guided Therapy in Newly Diagnosed Myeloma
Perrot, A., Lambert, J., Hulin, C., Pieragostini, A., Karlin, L., Arnulf, B., Rey, P., Garderet, L., Macro, M., Escoffre‐Barbe, M., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2505133 · Cited by 97
Self-citationBadros, A. Z., Foster, L. H., Anderson, L. D., Chaulagain, C. P., Pettijohn, E. M., Cowan, A. J., Costello, C. L., Larson, S. M., Sborov, D. W., Shain, K. H., et al. (2024) · Blood · doi:10.1182/blood.2024025746 · Cited by 80
Self-citationTouzeau, C., Perrot, A., Hulin, C., Manier, S., Macro, M., Chrétien, M., Karlin, L., Escoffre‐Barbe, M., Jacquet, C., Tiab, M., et al. (2024) · Blood · doi:10.1182/blood.2023023597 · Cited by 77
Self-citationHyaluronidase: structure, mechanism of action, diseases and therapeutic targets
Lu, J., Zhao, Z., Pan, L., Wu, H. C., Wang, S., Tong, X., & Wu, S. (2025) · Molecular Biomedicine · doi:10.1186/s43556-025-00299-y · Cited by 96
“…of hyaluronidase with other monoclonal agents such as trastuzumab-hyaluronidase-oysk [257], Darzalex Faspro (daratumumab-hyaluronidase-fihj) [258], Pertuzumab-Trastuzumab-Hyaluronidase-zzxf [259], rituximab and trastuzumab in combination with rHuPH20 [260] all showed similar efficacy and…”
NCCN Guidelines® Insights: Multiple Myeloma, Version 1.2025
Kumar, S. K., Callander, N. S., Adekola, K., Anderson, L. D., Jr., Baljević, M., Baz, R., Campagnaro, E. L., Costello, C. L., D'Angelo, C. R., Derman, B. A., et al. (2025) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2025.0023 · Cited by 70
Shi, Q., Paiva, B., Pederson, L., Dimier, N., Talpes, E., Prior, T. J., Órfão, A., Moreau, P., Sonneveld, P., Kumar, S. K., et al. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-24-02020 · Cited by 52
“…rate (ORR) has been used to support accelerated approval of novel regimens in MM. 7,8 However, current standards of care are routinely achieving an ORR of >90% 1,3,8-15 in some settings and therefore can no longer well differentiate ef fi cacy between control versus investigational arms in RCTs.”
Self-citationNavigating High-Risk and Ultrahigh-Risk Multiple Myeloma: Challenges and Emerging Strategies
Rees, M. J., D’Agostino, M., Leypoldt, L. B., Kumar, S. K., Weisel, K. C., & Gay, F. (2024) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_433520 · Cited by 55
“45,64 Data on the speci fi c role of lenalidomide 1 anti-CD38 MoABs in the context of maintenance only are not yet available.”
Self-citationPerrot, A., Touzeau, C., Lambert, J., Hulin, C., Caillot, D., Karlin, L., Arnulf, B., Rey, P., Garderet, L., Macro, M., et al. (2025) · Blood · doi:10.1182/blood.2024026230 · Cited by 47
Self-citationMateos, M.-V., Martínez-López, J., Rodriguez Otero, P., González-Calle, V., Gonzalez, M. S., Oriol, A., Gutiérrez, N. C., Ríos-Tamayo, R., Rosiñol, L., Alvarez Rivas, M. A., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.23.02771 · Cited by 39
“17 In the ISKIA study, in which car fi lzomib is the proteasome inhibitor, the uMRD rates after induction and consolidation with isatuximab-KRd or KRd following ASCT were 77% and 67%, respectively, and these data are not very different from ours, especially in the arm without monoclonal antibody.”
MethodSelf-citationRole of minimal residual disease assessment in multiple myeloma
Szalat, R. E., Anderson, K. C., & Munshi, N. C. (2024) · Haematologica · doi:10.3324/haematol.2023.284662 · Cited by 73
Engelhardt, M. M., Kortüm, K. M., Goldschmidt, H., & Merz, M. (2024) · Haematologica · doi:10.3324/haematol.2023.283058 · Cited by 70
“42,43 Therefore, induction therapy with a CD38 antibody in combination with a proteasome inhibitor, immunomodulatory drug and dexamethasone followed by ASCT and lenalidomide maintenance can be considered a standard of care for most TE NDMM patients today.”
Minimal Residual Disease as an Early Endpoint for Accelerated Drug Approval in Myeloma: A Roadmap
Landgren, O., & Devlin, S. M. (2024) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-24-0292 · Cited by 47
Chari, A., Kaufman, J. L., Laubach, J. P., Sborov, D. W., Reeves, B., Rodriguez, C., Silbermann, R. W., Costa, L. J., Anderson, L. D., Nathwani, N., et al. (2024) · Blood Cancer Journal · doi:10.1038/s41408-024-01088-6 · Cited by 40
Ntanasis‐Stathopoulos, I., Filippatos, C., Ntanasis‐Stathopoulos, A., Malandrakis, P., Kastritis, E., Tsitsilonis, O., Dimopoulos, M. A., Terpos, E., & Gavriatopoulou, M. (2025) · American Journal of Hematology · doi:10.1002/ajh.27582 · Cited by 32
“In total, 36 articles with results from 29 randomized controlled trials were included [2, 3, 19– 52 ].”
Self-citationCorre, J., Vincent, L., Moreau, P., Hébraud, B., Hulin, C., Béné, M. C., Broijl, A., Caillot, D., Delforge, M., Dejoie, T., et al. (2025) · Blood · doi:10.1182/blood.2024027620 · Cited by 33
Self-citationOpportunities and challenges for MRD assessment in the clinical management of multiple myeloma
Paiva, B., Shi, Q., Puig, N., Cedena, M., Órfão, A., Durie, B. G. M., Munshi, N. C., & Miguel, J. F. S. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01017-x · Cited by 41
“Considering that the new standard-of-care treatments for transplant-eligible patients with NDMM have been associated with PFS rates of ~85% at 4 years 71 , median PFS could potentially be 10 years or more.”
Banerjee, R. K., Biru, Y., Cole, C. E., Faiman, B. M., Midha, S., & Ailawadhi, S. (2024) · Blood Cancer Journal · doi:10.1038/s41408-024-01129-0 · Cited by 28
“As shown in Table 1, there are many dosing strategies that can improve a drug ’ s safety and even ef fi cacy but that – because they were not employed in the trials leading to regulatory approval – are often excluded from package inserts and dosing guidance [21, 23, 45 – 56].”
BackgroundTerpos, E., Malandrakis, P., Ntanasis‐Stathopoulos, I., Kostopoulos, I. V., Eleutherakis‐Papaiakovou, E., Kanellias, N., Spiliopoulou, V., Migkou, M., Fotiou, D., Theodorakakou, F., et al. (2025) · Blood · doi:10.1182/blood.2024027686 · Cited by 31
Self-citationMultiple Myeloma: The Role of Autologous Stem Cell Transplantation in the Era of Immunotherapy
Rocchi, S., Zannetti, B. A., Marconi, G., & Lanza, F. (2024) · Cells · doi:10.3390/cells13100853 · Cited by 34
Ebraheem, M. S., Chakraborty, R., Rochwerg, B. N., Visram, A., Mohyuddin, G. R., Venner, C. P., Sandhu, I., McCurdy, A. B. R., Facon, T. T. F., Mateos, M., et al. (2024) · Blood Advances · doi:10.1182/bloodadvances.2024014139 · Cited by 30
Joseph, N. S., Kaufman, J. L., Gupta, V. A., Hofmeister, C. C., Dhodapkar, M. V., Boise, L., Dicamillo, S., Roberts, D., Nooka, A. K., & Lonial, S. (2024) · Blood Cancer Journal · doi:10.1038/s41408-024-01120-9 · Cited by 26
“In sum, this randomized data is quite convincing and supports quadruplet induction therapy as the new standard of care [6].”
ResultGay, F., Marchetti, E., & Bertuglia, G. (2025) · Hematological Oncology · doi:10.1002/hon.70067 · Cited by 37
Self-citationProdrugs in Oncology: Bioactivation and Impact on Therapeutic Efficacy and Toxicity
Kurian, R., & Wang, H. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26030988 · Cited by 28
“Typically, treatment plans for multiple myeloma patients include immunomodulatory drugs such as lenalidomide and proteo-some inhibitors such as bortezomib [51,52].”
Giri, S., Dhakal, B., Callander, N. S., Medvedova, E., Godby, K. N., Dholaria, B., Bal, S., Ravi, G., Chhabra, S., Silbermann, R. W., et al. (2025) · Blood · doi:10.1182/blood.2024027674 · Cited by 27
Advances in adoptive cellular immunotherapy and therapeutic breakthroughs in multiple myeloma
Pu, J., Liu, T., Sharma, A., Jiang, L., Wei, F., Ren, X., Schmidt‐Wolf, I. G. H., & Hou, J. (2024) · Experimental Hematology and Oncology · doi:10.1186/s40164-024-00576-6 · Cited by 24
“These findings were confirmed by the phase III PERSEUS study (NCT03710603), where daratumumab plus VRd significantly improved PFS and MRD negativity rates [81].”
ResultWaldschmidt, J. M., Rasche, L., Kortüm, K. M., & Einsele, H. (2024) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2024.11.012 · Cited by 23
Self-citationYohannan, B., Rees, M. J., Gertz, M. A., Dispenzieri, A. A., Kapoor, P., Buadi, F. K., Dingli, D., Leung, N., Lacy, M. Q., Hayman, S. R., et al. (2025) · Blood Neoplasia · doi:10.1016/j.bneo.2025.100092 · Cited by 27
Renal AL Amyloidosis: Updates on Diagnosis, Staging, and Management
Shafqat, A., Elmaleh, H., Mushtaq, A. H., Firdous, Z., Ashruf, O. S., Mukhopadhyay, D., Ahmad, M., Ahmad, M., Raza, S., & Anwer, F. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13061744 · Cited by 24
“…as well as to lenalidomide maintenance therapy, significantly improved progression-free survival at 48 months (HR, 0.42; 95% CI, 0.30 to 0.59; p < 0.001), as well as secondary endpoints of complete response (87.9 vs. 70.1%, p < 0.001) and MRD negativity (75.2% vs. 47.5%, p < 0.001) [123].”
BackgroundInfluentialDerman, B. A., Cooperrider, J. H., Rosenblatt, J. M., Avigan, D., Rampurwala, M. M., Barnidge, D. R., Major, A., Karrison, T. G., Jiang, K., Ramsland, A., et al. (2024) · Blood Cancer Journal · doi:10.1038/s41408-024-01045-3 · Cited by 21
Monoclonal immunoglobulin crystalline nephropathies
Nasr, S. H., Sirac, C., Leung, N., et al. (2024) · Kidney International · doi:10.1016/j.kint.2024.02.027 · Cited by 17
Mitigating time toxicity in lymphoma and multiple myeloma
Di, M., Su, C. T., Cowan, A. J., Gopal, A. K., & Banerjee, R. K. (2024) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2024.2352086 · Cited by 21
“…inhibitors (Pis) such as subcutaneous bortezomib or intravenous carfilzomib are core components of many MM treatment regimens in both the frontline and R/R settings. with bortezomib, many trials have used twice-weekly dosing on Days 1, 4, 8, and 11 of 21-day cycles during induction [47,52–55].”
Lasa, M., González, C., Notarfranchi, L., Zherniakova, A., Alignani, D., Burgos, L., Calasanz, M. J., Rodríguez‐Otero, P., Pérez, J. J., Gómez, C., et al. (2025) · Blood · doi:10.1182/blood.2025029234 · Cited by 17
Self-citationEuropean Myeloma Network Consensus Statement on Functional High‐Risk Multiple Myeloma
Lim, S., Engelhardt, M. M., Terpos, E., Gay, F., van de Donk, N. W. C. J., Einsele, H., Sonneveld, P., Kaiser, M., Boccadoro, M., & Spencer, A. G. (2025) · American Journal of Hematology · doi:10.1002/ajh.70070 · Cited by 20
Self-citationGiles, H. V., & Karunanithi, K. (2024) · Antibodies · doi:10.3390/antib13010019 · Cited by 23
“There have also been extensive efforts made to identify novel assays and modifications of the existing assays that can enhance sensitivity given the deep responses obtained in the majority of patients with plasma cell disorders treated with modern chemotherapy and immunotherapy regimens [15–20].”
BackgroundHartley-Brown, M. A., Weisel, K. C., Bitetti, J., Carter, J. A., McNamara, S., Purser, M. F., Palumbo, A., & Richardson, P. G. G. (2024) · British Journal of Haematology · doi:10.1111/bjh.19627 · Cited by 20
Askeland, F. B., Haukås, E., Slørdahl, T. S., Klostergaard, A., Alexandersen, T., Osnes, L., Lysén, A., Abdollahi, P., Nielsen, L. K., Hermansen, E., et al. (2025) · The Lancet Haematology · doi:10.1016/s2352-3026(24)00347-8 · Cited by 44
Self-citationKorst, C. L. B. M., Tahri, S., Duetz, C., Bruins, W. S. C., de Jonge, A. V., de Jong, M. M. E., Fokkema, C., Smits, F., Groen, K., Verkleij, C. P. M., et al. (2025) · Blood · doi:10.1182/blood.2024026455 · Cited by 22
Self-citationFilho, J. T. D. S., Cantadori, L. O., Crusoé, E. D. Q., Hungria, V., & Maiolino, Â. (2025) · Blood Cancer Journal · doi:10.1038/s41408-025-01253-5 · Cited by 20
Barbieri, E., Martino, E. A., Rivolti, E., Quaresima, M., Vigna, E., Neri, A., Morabito, F., & Gentile, M. (2024) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2024.2357382 · Cited by 14
“Indeed, the APOLLO trial [52], investigating daratumumab plus pomalidomide and dexamethasone (DaraPd) in RRMM, and the PERSEUS trial [53], investigating daratumumab plus VRd (DaraVRd) in transplant-eligible (TE) NDMM, used ‘traditional’ HiRCA criteria, as defined by the R-ISS, which did not include…”
MethodMRD accelerating myeloma drug development
Costa, L. J. (2024) · Blood · doi:10.1182/blood.2024025421 · Cited by 13
Beyond BCMA: the next wave of CAR T cell therapy in multiple myeloma
Miller, K. C., Hashmi, H., & Rajeeve, S. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1398902 · Cited by 24
LILRB4 regulates multiple myeloma development through STAT3-PFKFB1 pathway
Xie, L., Chen, C., Zhang, T., Yang, W., Zheng, D., Cao, L., Yuan, J., Xu, Y., Zhang, Y., Liu, L., et al. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-06883-4 · Cited by 12
“Animal experiments were evaluated and approved by our institution and performed under the Guideline for Animal Care at Shanghai Jiao Tong University, School of Medicine.”
BackgroundMethodLiu, Y., Mo, C. C., Hartley-Brown, M. A., Sperling, A. S., Midha, S., Yee, A. J., Bianchi, G., Piper, C., Tattersall, A., Nadeem, O., et al. (2024) · Expert Review of Hematology · doi:10.1080/17474086.2024.2382897 · Cited by 16
“The standards of care for NDMM are evolving to incorporate quadruplet regimens comprising a PI, an IMiD, and an CD38 mAb [12], with long-term single-agent or doub-let maintenance [11] or potentially triplet maintenance for patients with high-risk disease [157–159].”
InfluentialSelf-citationNatural killer cell biology and therapy in multiple myeloma: challenges and opportunities
Bisht, K. K., Merino, A. M., Igarashi, R., et al. (2024) · Experimental Hematology and Oncology · doi:10.1186/s40164-024-00578-4 · Cited by 12
Bhutani, M., Robinson, M. M., Foureau, D., Atrash, S., Paul, B. A., Guo, F., Grayson, J. M., Foureau, A. V. I., Pineda‐Roman, M., Varga, C., et al. (2024) · Blood Advances · doi:10.1182/bloodadvances.2024014417 · Cited by 12
Schindler-Wnek, K., Stahringer, A., Heimer, N., Koehl, U., Fricke, S., & Schmiedel, D. (2025) · OncoImmunology · doi:10.1080/2162402x.2025.2546443 · Cited by 15
Besliu, C., Tănase, A., Rotaru, I., Espinoza, J., Vidal, L., Poelman, M., Juan, M., de Larrea, C. F., & Saini, K. S. (2025) · Cancers · doi:10.3390/cancers17030525 · Cited by 17
“…MRD-negativity while the MRD-negativity status (10 − 5 sensitivity threshold) was 75.2% in the Dara-VRd arm and 47.5% in the VRd arm ( p < 0.001) [26]. status (10 sensitivity 75.2% in the Dara-VRd arm and 47.5% in the VRd arm ( p < 0.001) [26]. trial The BENEFIT trial was designed to evaluate…”
InfluentialPasvolsky, O., Marcoux, C., Milton, D. R., et al. (2024) · Blood Cancer Journal · doi:10.1038/s41408-024-01165-w · Cited by 11
“Increasing use of daratumumab in the frontline setting for transplant-eligible MM patients [30 – 32] has also raised concerns about its impact on stem cell mobilization and collection [33, 34].”
BackgroundPaul, B. A., Anwer, F., Raza, S., Mammadzadeh, A., Khasawneh, B., Shatnawi, S., McGuirk, J. P., Ahmed, N., Mahmoudjafari, Z., Mushtaq, M. U., et al. (2024) · Cancers · doi:10.3390/cancers16172938 · Cited by 11
“Specifically, the addition of the anti-CD38 antibodies dara-tumumab and isatuximab to multiple triplet backbones has shown unrivaled depth of response and PFS advantage [15,18,23,28,35–37].”
BackgroundReal‐World Evidence on Prognostic Value of MRD in Multiple Myeloma Using Flow Cytometry
Muroňová, L., Souček, O., Žihala, D., Ševčíková, T., Popková, T., Plonková, H., Venglár, O., Pour, L., Štork, M., Říhová, L., et al. (2024) · European Journal Of Haematology · doi:10.1111/ejh.14316 · Cited by 12
Yee, A. J., Laubach, J. P., Campagnaro, E. L., Lipe, B. C., Nadeem, O., Friedman, R. S., Cole, C. E., O’Donnell, E., Bianchi, G., Branagan, A. R., et al. (2025) · Blood Advances · doi:10.1182/bloodadvances.2024014717 · Cited by 18
Alshammari, F., Alrajhi, A. M., & Howaidi, J. (2025) · Hematology · doi:10.1080/16078454.2024.2448898 · Cited by 14
“[17].”
Bertamini, L., Fokkema, C., Rodríguez‐Otero, P., van Duin, M., Terpos, E., D’Agostino, M., van der Velden, V. H. J., van de Donk, N. W. C. J., Delforge, M., Driessen, C., et al. (2025) · Blood · doi:10.1182/blood.2025030113 · Cited by 13
Self-citationVerbruggen, S. W., Freeman, C. L. L., & Freeman, F. E. (2024) · Cancers · doi:10.3390/cancers16050889 · Cited by 11
“Notably, the integration of these novel agents into frontline therapy, maintenance, and relapse settings has led to prolonged survival rates and deeper remissions [10].”
BackgroundTreatment of Multiple Myeloma: ASCO–Ontario Health (Cancer Care Ontario) Living Guideline
Hicks, L. K., Messersmith, H. J., Hadidi, S. S. A. A., Banerjee, R. K., Derman, B. A., Kumar, S. K., Wildes, T. M., Bal, S., Bhella, S., Chmielewski, C., et al. (2026) · Journal of Clinical Oncology · doi:10.1200/jco-25-02587 · Cited by 17
Zhang, L., Chen, Z., Yang, Q., & Liu, M. (2024) · Materials Technology · doi:10.1080/10667857.2024.2335848 · Cited by 9
“Its efficacy and tolerability have made it a key component of treatment strategies for both newly diagnosed and relapsed/refractory multiple myeloma [1–6].”
Morè, S., Corvatta, L., Manieri, V. M., Morsia, E., & Offidani, M. (2024) · Cancers · doi:10.3390/cancers16122263 · Cited by 10
Bigi, F., Manzato, E., Barbato, S., Talarico, M., Puppi, M., Masci, S., Sacchetti, I., Restuccia, R., Iezza, M., Rizzello, I., et al. (2024) · Pharmaceuticals · doi:10.3390/ph17070944 · Cited by 14
Self-citationSingle versus tandem autologous stem cell transplantation in newly diagnosed multiple myeloma
Grieb, N., Oeser, A., Ferle, M., Hanke, F., Flossdorf, S., Sauer, S., Goldschmidt, H., Müller‐Tidow, C., Salwender, H.-J., Fenk, R. R., et al. (2024) · Bone Marrow Transplantation · doi:10.1038/s41409-024-02490-1 · Cited by 12
“Nevertheless, even in the era of quadruplet induction therapies with anti-CD38 antibodies in combination with proteasome inhibitors (PI), immunomodulatory drugs (IMiDs) and steroids, ASCT plays an integral role to deepen responses that last for years or even decades [1 – 5].”
Self-citationNovel Treatment Options for Multiple Myeloma
Portuguese, A. J., Banerjee, R. K., Chen, G. Z., Reddi, S., & Cowan, A. J. (2025) · JCO Oncology Practice · doi:10.1200/op-24-00752 · Cited by 17
Treatment of myeloma bone disease: When, how often, and for how long?
Gundesen, M. T., Schjesvold, F. H., & Lund, T. (2025) · Journal of bone oncology · doi:10.1016/j.jbo.2025.100680 · Cited by 12
“While relevant at the time, the induction and maintenance were suboptimal compared to the current SOC which often include combinations of bortezomib, lenalidomide, dar-atumumab and lenalidomide [48,49].”
Self-citationAttrition rates and treatment outcomes in multiple myeloma: real-world data over a 40-year period
Rodríguez‐Lobato, L. G., de Daniel, A., Pereira, A., de Larrea, C. F., Tovar, N., Cibeira, M. T., Moreno, D. F., Mateos, J. M., Llobet, N., Carcelero, E., et al. (2025) · Blood Cancer Journal · doi:10.1038/s41408-025-01311-y · Cited by 17
Self-citationBruins, W. S. C., Smits, F., Duetz, C., Groen, K., Korst, C. L. B. M., de Jonge, A. V., Verkleij, C. P. M., Rentenaar, R., Cosovic, M., Eken, M., et al. (2025) · Blood · doi:10.1182/blood.2025028587 · Cited by 14
Self-citationTrends in Outcomes After Upfront Autologous Transplant for Multiple Myeloma Over Three Decades
Pasvolsky, O., Marcoux, C., Dai, J., Milton, D. R., Tanner, M. R., Syed, N., Bashir, Q., Srour, S. A., Saini, N. Y., Lin, P. Y., et al. (2024) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2024.06.001 · Cited by 13
Zanwar, S., & Kumar, S. K. (2024) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2024.2443550 · Cited by 9
“…the Phase 3 PeRSeUS trial, comparing daratu-mumab, bortezomib, lenalidomide, and dexamethasone (Dara-vRd)] with vRd, demonstrated an improved PFS with Dara-vRd, including within the small sub-group of patients with HRMM with a 40% reduction in the risk of progression or death with D-vRd [47].”
Targeting Ubiquitin–Proteasome system (UPS) in treating osteoarthritis
Wong, P., & Kamarul, T. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.177237 · Cited by 8
Rubinstein, S. M., Mohsin, A., Banerjee, R., Ma, W., Mishra, S., Kwok, M., Yang, P. C., Warner, J. L., & Cowan, A. J. (2025) · Frontiers in Digital Health · doi:10.3389/fdgth.2025.1569554 · Cited by 12
Mirgh, S. P., Bagal, B. P., Punatar, S. B., Gokarn, A. G., Jindal, N., Chichra, A., Nayak, L., Hiregoudar, S., Poojary, M., Saha, S., et al. (2025) · Cancer Medicine · doi:10.1002/cam4.71068 · Cited by 9
“Lenalidomide-based triplets (Bortezomib- lenalidomide-dexamethasone—VRd) [3, 4] or quadruplets [Daratumumab + VRd] [5, 6], followed by autologous stem-cell transplant (ASCT) and lenalidomide maintenance, is standard of care treatment in newly diagnosed MM patients who are transplant eligible (TE).”
Management recommendations for kidney transplantation in patients with plasma cell dyscrasia
Murakami, N., Blosser, C. D., Webber, A. B., Gupta, G., Singh, N., Boppana, S., Master, S. R., Parasuraman, R. K., Campagnaro, E. L., Java, A., et al. (2025) · Kidney International · doi:10.1016/j.kint.2025.07.011 · Cited by 11
Cani, L., Parikh, R., Joseph, N. S., Gupta, V. A., Hofmeister, C. C., Kaufman, J. L., Nooka, A. K., Lonial, S., & Mina, R. (2026) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2026.03.003 · Cited by 8
Self-citationComorbidities and survival of multiple myeloma patients diagnosed in Finland between 2000 and 2021
Kysenius, K., Anttalainen, A., Toppila, I., Miettinen, T. A., Lassenius, M. I., Lievonen, J., Partanen, A., Silvennoinen, R. H., & Putkonen, M. (2024) · Annals of Hematology · doi:10.1007/s00277-024-05865-y · Cited by 12
“In addition, cumulative data exist on quadruplet regimens including CD38Ab with remarkable progression-free survival (PFS) benefit in trans - plant-eligible patients with newly diagnosed MM [11, 12].”
BackgroundVenner, C. P., Duggan, P. R., Song, K., Reece, D. E., Sharma, S., Su, J., Jimenez-Zepeda, V. H., McCurdy, A. B. R., Louzada, M., Mian, H. S., et al. (2024) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2024.06.030 · Cited by 9
Sidana, S., Bankova, A. K., Hosoya, H., Kumar, S. K., Holmes, T. H., Tamaresis, J. S., Le, A., Muffly, L. S., Maysel-Auslender, S., Johnston, L., et al. (2024) · Blood Cancer Journal · doi:10.1038/s41408-024-01152-1 · Cited by 10
Wijnands, C., Karel, P. G. A., Gloerich, J., Armony, G., Tzasta, A., Angelino, C. M. D. K., Stéfano, L. D., Bonifay, V., Luider, T. M., VanDuijn, M. M., et al. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17010135 · Cited by 7
“…of quadruplet induction treatment including a CD38-targeting therapeutic antibody (t-Ab) (e.g., daratumumab), proteasome inhibitor (e.g., bortezomib), immunomodulatory agent (e.g., lenalidomide), and dexamethasone followed by high dose melphalan and autologous stem cell transplantation [3–5].”
Self-citationThe Role of Extracorporeal Therapy in Light Chain Cast Nephropathy
Heybeli, C., Simone, E. D., & Leung, N. (2025) · American Journal of Nephrology · doi:10.1159/000547342 · Cited by 7
“Dar-atumumab improved progression-free survival of transplant-eligible newly diagnosed myeloma patients in combination with other anti-myeloma agents for induction and consolidation or as monotherapy for maintenance [83, 84].”
Sutanto, H., Romadhon, P. Z., Fatmawati, V. R., Waitupu, A., Ansharullah, B. A., Rachma, B., Elisa, E., Pratiwi, L., & Adytia, G. J. (2025) · Hemato · doi:10.3390/hemato6030029 · Cited by 8
Peptide-Based Targeted Covalent Inhibitors
Cao, F., Guo, R.-C., Zhang, Z., & Yu, Z. (2025) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.5c18100 · Cited by 8
Gay, F., Roeloffzen, W., Dimopoulos, M. A., Rosiñol, L., van der Klift, M., Mina, R., Oriol, A., Katodritou, E., Wu, K. L., Rodríguez‐Otero, P., et al. (2026) · Nature Medicine · doi:10.1038/s41591-026-04282-0 · Cited by 12
“The rates of infections were also similar in the two arms, despite the higher rates of neutropenia during induction in patients receiving Isa-KRd (in line with other reports on quadruplets in the upfront treatment) 2,32 .”
Self-citationRaab, M. S., Weinhold, N., Kortüm, K. M., Krönke, J., Fenk, R. R., Weisel, K. C., Podola, L., Bertsch, U., Brobeil, A., Mersi, J., et al. (2026) · Nature Medicine · doi:10.1038/s41591-026-04471-x · Cited by 11
Self-citationLipid levels and multiple myeloma risk: insights from Meta-analysis and mendelian randomization
Zhu, W., Charwudzi, A., Li, Q., Zhai, Z., Hu, L., & Pu, L. (2024) · Lipids in Health and Disease · doi:10.1186/s12944-024-02289-5 · Cited by 7
“Despite recent treatment advancements improving patient outcomes, identifying risk factors remains crucial for reducing MM incidence and enhancing prognosis [1, 2].”
BackgroundOsama, M., Khan, M. H., Khan, S., Hussain, A., Tahir, A., Ullah, M., Afridi, A., Ullah, U., & Rehman, W. U. (2025) · Therapeutic Advances in Hematology · doi:10.1177/20406207251314289 · Cited by 8
Chen, B., Liu, J., Zhang, Y., Shih, C., Zhu, D., Zhang, G., Xiao, F., Zhong, L., Zhang, M., Ng, L. G., et al. (2025) · Advanced Science · doi:10.1002/advs.202415695 · Cited by 14
Hughes, M. S., Balev, M., Radhakrishnan, J., Bhutani, D., Mapara, M. Y., Lentzsch, S., & Chakraborty, R. (2025) · European Journal Of Haematology · doi:10.1111/ejh.14403 · Cited by 6
Gay, F., Zamagni, E., Cole, C. E., Scheid, C., Hultcrantz, M. L., Chorąży, J., Iheanacho, I., Pandey, A., Bitetti, J., Boytsov, N. N., et al. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1550644 · Cited by 10
“Novel combinations, particularly quadruplet regimens, have emerged as frontline options in patients who were transplant ineligible and, more recently, transplant eligible, resulting in improved progression-free survival (PFS) and overall survival (OS) (4 – 6).”
Self-citationWang, L., Yang, W. C., Wang, Y., Niu, T., Fu, R., Zhong, Y., Qian, W., Ding, K., Sun, K., Liu, H., et al. (2025) · BMC Cancer · doi:10.1186/s12885-025-13925-3 · Cited by 10
Novellis, D. D., Scala, P., Giudice, V., & Selleri, C. (2025) · Cells · doi:10.3390/cells14110776 · Cited by 7
“In the ongoing PERSEUS study (NCT03710603), maintenance with lenalidomide and daratu-mumab is being tested in both standard and high-genetic risk patients [57,76].”
Minimal Residual Disease Negativity as the Primary Goal of Multiple Myeloma Therapy
Cooperrider, J. H., & Derman, B. A. (2025) · Drugs · doi:10.1007/s40265-025-02232-7 · Cited by 9
“Combination therapy in the post-autoSCT setting, such as with Dara-R or KRd, carry at least a PFS benefit over monotherapy and can be de-escalated on the basis of MRD negativity [89, 121].”
Influential
Metadata
- Authors
- Sonneveld, P., Dimopoulos, M. A., Boccadoro, M., Quach, H., Ho, P. J., Beksac, M., Hulin, C., Antonioli, E., Leleu, X., Mangiacavalli, S., Perrot, A., Cavo, M., Belotti, A., Broijl, A., Gay, F., Mina, R., Nijhof, I. S., van de Donk, N. W. C. J., Katodritou, E., Schjesvold, F., Sureda Balari, A., Rosiñol, L., Delforge, M., Roeloffzen, W., Silzle, T., Vangsted, A., Einsele, H., Spencer, A., Hajek, R., Jurczyszyn, A., Lonergan, S., Ahmadi, T., Liu, Y., Wang, J., Vieyra, D., van Brummelen, E. M. J., Vanquickelberghe, V., Sitthi-Amorn, A., de Boer, C. J., Carson, R., Rodriguez-Otero, P., Bladé, J., & Moreau, P.
- Affiliations
- University Medical Center Groningen (NL)
- The University of Sydney (AU)
- From the Department of Hematology, Erasmus MC Cancer Institute, Rotterdam (P.S., A. Broijl, S.L.), the Department of Hematology, Amsterdam University Medical Center and Vrije Universiteit Amsterdam, Amsterdam (I.S.N., N.W.C.J.D.), the Department of Hematology, St. Antonius Hospital, Nieuwegein (I.S.N.), University Medical Center Groningen, Groningen (W.R.), and Janssen Research and Development, Leiden (E.M.J.B., C.J.B.) — all in the Netherlands; National and Kapodistrian University of Athens, Athens (M.A.D.), and the Department of Hematology, Theagenion Cancer Hospital, Thessaloniki (E.K.) — both in Greece; the Myeloma Unit, Division of Hematology, University of Turin and Azienda Ospedaliero-Universitaria (AOU) Città della Salute e della Scienza di Torino (M. Boccadoro), the Division of Hematology 1, AOU Città della Salute e della Scienza di Torino (F.G., R.M.), and the Department of Molecular Biotechnology and Health Sciences, University of Turin (F.G., R.M.), Turin, the Department of Hematology, Careggi ...
- Oslo University Hospital (NO)
- Jagiellonian University (PL)
- ORCID
- Sonneveld, Pieter
- Dimopoulos, Meletios A.
- Boccadoro, Mario
- Quach, Hang
- Ho, P. Joy
- Hulin, Cyrille
- Antonioli, Elisabetta
- Leleu, Xavier
- Mangiacavalli, Silvia
- Perrot, Aurore
- Belotti, Angelo
- Broijl, Annemiek
- Gay, Francesca
- Mina, Roberto
- Katodritou, Eirini
- Schjesvold, Fredrik
- Rosiñol, Laura
- Delforge, Michel
- Roeloffzen, Wilfried
- Silzle, Tobias
- Vangsted, Annette
- Einsele, Hermann
- Spencer, Andrew
- Jurczyszyn, Artur
- Ahmadi, Tahamtan
- Liu, Yanfang
- Wang, Jianping
- Sitthi-Amorn, Anna
- Bladé, Joan
- Moreau, Philippe
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2024-01-25
- Volume
- 390
- Issue
- 4
- Pages
- 301-313
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4389606680
- Cited by
- 599
- References
- 23
- Citations by year
- 2026: 198 · 2025: 252 · 2024: 145
- FWCI
- 123.04
- Type
- journal article
- Language
- en
- Open access
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Leiden Repository (Leiden University) (submittedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion, other-oa)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion, other-oa)
- Homo Politicus (Academy of Humanities and Economics in Lodz) (submittedVersion, cc-by-nc-nd)
- CINECA IRIS Institutial Research Information System (University of Genoa) (submittedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
- Lirias (KU Leuven) (submittedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
- CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro) (submittedVersion)
- Funders
- European Myeloma Network in collaboration with Janssen Research & Development, LLC
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Keywords
- multiple myeloma, daratumumab, bortezomib, lenalidomide, dexamethasone, subcutaneous daratumumab, CD38, newly diagnosed multiple myeloma, progression-free survival, minimal residual disease, complete response, lenalidomide maintenance, neutropenia
- MeSH terms
- Bortezomib, Lenalidomide, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Dexamethasone, Humans, Membrane Glycoproteins, Multiple Myeloma, Disease Progression, ADP-ribosyl Cyclase 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.


